The company was founded in 2002, mainly engaged in proprietary Chinese medicine and chemical preparation research and development, production and sales, the company daily production and sales of 68 varieties of drugs, the number of employees at the end of 2013 was 510. The company's main business is mainly general medicine, and its products are related to cough and expectorant, kidney tonifying and anti-infective drugs, including Zhikebao tablets, Jinkui Shenqi tablets, erythromycin enteric-coated tablets, erythromycin tablets, mycophenol tablets and other high-quality varieties. From 2011 to 2013, the company's operating income was 305 million, 341 million and 343 million respectively, the compound growth rate was 5.98%, the net profit was 70 million, 79 million and 81 million respectively, and the compound growth rate was 7.5%, maintaining a steady growth trend.

The company intends to issue no more than 25 million RMB common shares to the public, accounting for 25.00% of the total share capital after the issue and offering.

Reasonable value range: 17.6-22 yuan

Considering the company's discovery of 25 million shares, we estimate that the company's EPS (corresponding to post-IPO share capital) from 2014 to 2016 is 0.88,0.96 and 1.04 yuan, respectively.